Merck & Co., Inc. News Headlines

$76.61
-0.62 (-0.80 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$76.16
$77.22
50-Day Range
$72.40
$79.87
52-Week Range
$71.71
$87.80
Volume19.30 million shs
Average Volume12.06 million shs
Market Capitalization$193.98 billion
P/E Ratio27.76
Dividend Yield3.37%
Beta0.4

Merck & Co., Inc. (NYSE MRK) News Headlines Today

SourceHeadline
Merck & Co., Inc. (NYSE:MRK) Rating Reiterated by ArgusMerck & Co., Inc. (NYSE:MRK) Rating Reiterated by Argus
marketbeat.com - May 26 at 8:21 AM
Can These 3 Dow Laggards Make a Second Half Comeback? (MRK)Can These 3 Dow Laggards Make a Second Half Comeback? (MRK)
marketbeat.com - April 22 at 3:01 PM
3 Stocks Near 52-Week Lows Ready to Buy3 Stocks Near 52-Week Lows Ready to Buy
marketbeat.com - April 9 at 1:24 PM
Gov. Ducey’s decision to block COVID-19 policies for universities is ‘not based in science’: DoctorGov. Ducey’s decision to block COVID-19 policies for universities is ‘not based in science’: Doctor
finance.yahoo.com - June 18 at 2:25 PM
10 Best Healthcare Stocks to Buy According to Hedge Funds10 Best Healthcare Stocks to Buy According to Hedge Funds
finance.yahoo.com - June 17 at 5:09 PM
This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 MarketThis Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market
finance.yahoo.com - June 17 at 12:08 PM
MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
finance.yahoo.com - June 17 at 12:08 PM
Merck to Participate in the Guggenheim Biopharma Strategy SeriesMerck to Participate in the Guggenheim Biopharma Strategy Series
finance.yahoo.com - June 17 at 7:07 AM
Merck & Co., Inc. (NYSE:MRK) Sees Strong Trading VolumeMerck & Co., Inc. (NYSE:MRK) Sees Strong Trading Volume
americanbankingnews.com - June 16 at 12:44 PM
Is Merck & Co., Inc. (MRK) Going to Burn These Hedge Funds?Is Merck & Co., Inc. (MRK) Going to Burn These Hedge Funds?
finance.yahoo.com - June 14 at 7:28 PM
$1.58 EPS Expected for Merck & Co., Inc. (NYSE:MRK) This Quarter$1.58 EPS Expected for Merck & Co., Inc. (NYSE:MRK) This Quarter
americanbankingnews.com - June 13 at 5:14 AM
US STOCKS-Wall Street set to inch higher, meme stocks extend rallyUS STOCKS-Wall Street set to inch higher, 'meme' stocks extend rally
finance.yahoo.com - June 9 at 1:00 PM
US STOCKS-Wall Street edges higher on tech gains, meme stocks rallyUS STOCKS-Wall Street edges higher on tech gains, 'meme' stocks rally
finance.yahoo.com - June 9 at 1:00 PM
US STOCKS-S&P 500 flirts with record high, meme rally rolls onUS STOCKS-S&P 500 flirts with record high, 'meme' rally rolls on
finance.yahoo.com - June 9 at 1:00 PM
New daily COVID-19 cases and deaths rise again as concerns over delta variant and Biden vaccination target for July 4 increaseNew daily COVID-19 cases and deaths rise again as concerns over delta variant and Biden vaccination target for July 4 increase
finance.yahoo.com - June 9 at 1:00 PM
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
finance.yahoo.com - June 9 at 8:00 AM
Merck enters $1.2 billion agreement to supply U.S. government with potential COVID-19 treatmentMerck enters $1.2 billion agreement to supply U.S. government with potential COVID-19 treatment
finance.yahoo.com - June 9 at 8:00 AM
UPDATE 1-U.S. to buy about 1.7 mln courses of Mercks COVID-19 treatment for $1.2 blnUPDATE 1-U.S. to buy about 1.7 mln courses of Merck's COVID-19 treatment for $1.2 bln
finance.yahoo.com - June 9 at 8:00 AM
Merck/Eisais Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to SunitinibMerck/Eisai's Keytruda-Lenvima Combo Results in Better Health-Related Quality of Life Measures Compared to Sunitinib
finance.yahoo.com - June 7 at 1:29 PM
Merck & Co., Inc. (NYSE:MRK) PT Lowered to $93.00 at Truist SecuritiesMerck & Co., Inc. (NYSE:MRK) PT Lowered to $93.00 at Truist Securities
americanbankingnews.com - June 7 at 11:59 AM
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual MeetingNew Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
finance.yahoo.com - June 7 at 8:29 AM
Merck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of "Buy" from AnalystsMerck & Co., Inc. (NYSE:MRK) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - June 4 at 10:58 AM
Merck Completes Womens Health Organon SpinoffMerck Completes Women's Health Organon Spinoff
finance.yahoo.com - June 3 at 5:51 PM
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
finance.yahoo.com - June 3 at 5:51 PM
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA TrialLYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
finance.yahoo.com - June 3 at 5:51 PM
Merck & Co., Inc. (NYSE:MRK) Price Target Lowered to $99.00 at SVB LeerinkMerck & Co., Inc. (NYSE:MRK) Price Target Lowered to $99.00 at SVB Leerink
americanbankingnews.com - June 3 at 10:24 AM
Merck Announces Completion of Organon & Co. SpinoffMerck Announces Completion of Organon & Co. Spinoff
finance.yahoo.com - June 3 at 7:36 AM
Is Merck and Co. (MRK) A Smart Long-Term Buy?Is Merck and Co. (MRK) A Smart Long-Term Buy?
finance.yahoo.com - June 1 at 2:49 PM
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United StatesMerck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
finance.yahoo.com - June 1 at 9:49 AM
Merck & Co. to remain in Dow Jones Industrial Average after Spin-off TransactionMerck & Co. to remain in Dow Jones Industrial Average after Spin-off Transaction
finanznachrichten.de - May 28 at 10:21 AM
Merck & Co., Inc.s (MRK) Hold Rating Reaffirmed at ArgusMerck & Co., Inc.'s (MRK) Hold Rating Reaffirmed at Argus
americanbankingnews.com - May 26 at 9:56 AM
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal CancerMerck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
nasdaq.com - May 25 at 2:18 PM
Merck Announces Third-Quarter 2021 DividendMerck Announces Third-Quarter 2021 Dividend
finance.yahoo.com - May 25 at 2:18 PM
Merck & Co., Inc.: Downgrading to HOLD ahead of Organon spinoffMerck & Co., Inc.: Downgrading to HOLD ahead of Organon spinoff
finance.yahoo.com - May 20 at 1:33 PM
Mercks Next-Gen Pneumococcal Conjugate Vaccine Shows Efficacy In Pediatric TrialsMerck's Next-Gen Pneumococcal Conjugate Vaccine Shows Efficacy In Pediatric Trials
finance.yahoo.com - May 20 at 1:33 PM
10 Best Dividend Stocks to Buy According to Billionaire Richard Chilton10 Best Dividend Stocks to Buy According to Billionaire Richard Chilton
finance.yahoo.com - May 20 at 8:32 AM
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate VaccineMerck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
finance.yahoo.com - May 20 at 8:32 AM
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - May 13 at 10:02 AM
Merck Declares Record Date and Dividend for the Organon & Co. SpinoffMerck Declares Record Date and Dividend for the Organon & Co. Spinoff
finance.yahoo.com - May 7 at 1:21 PM
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial CarcinomaMerck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
finance.yahoo.com - May 6 at 7:17 AM
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research ProgramMerck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
finance.yahoo.com - May 6 at 7:17 AM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction AdenocarcinomaFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
finance.yahoo.com - May 5 at 6:42 PM
Merck Reports Disappointing 1Q Results; Street Maintains A Strong BuyMerck Reports Disappointing 1Q Results; Street Maintains A Strong Buy
finance.yahoo.com - April 30 at 7:14 PM
BeyondSpring Inc. (BYSI) Q1 2021 Earnings Call TranscriptBeyondSpring Inc. (BYSI) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 30 at 7:14 PM
Merck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts VaccinesMerck (MRK) Q1 Earnings & Sales Miss, COVID-19 Hurts Vaccines
nasdaq.com - April 29 at 2:51 PM
Merck & Co: Q1 Earnings InsightsMerck & Co: Q1 Earnings Insights
benzinga.com - April 29 at 8:21 AM
Merck Announces First-Quarter 2021 Financial ResultsMerck Announces First-Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 8:21 AM
UPDATE 1-Merck quarterly profit falls on COVID-19 hitUPDATE 1-Merck quarterly profit falls on COVID-19 hit
finance.yahoo.com - April 29 at 8:21 AM
Merck sees bigger 2021 sales hit after first quarter feels pandemic painMerck sees bigger 2021 sales hit after first quarter feels pandemic pain
ca.finance.yahoo.com - April 29 at 8:21 AM
Merck stock drops after adjusted profit surprisingly falls, revenue comes up shortMerck stock drops after adjusted profit surprisingly falls, revenue comes up short
finance.yahoo.com - April 29 at 8:21 AM
Merck Earnings Fell Short of Expectations. Here’s What Caused the Miss.Merck Earnings Fell Short of Expectations. Here’s What Caused the Miss.
finance.yahoo.com - April 29 at 8:21 AM
Top Pharma Giants Expected to Be Most Active in M&ATop Pharma Giants Expected to Be Most Active in M&A
finance.yahoo.com - April 27 at 7:01 PM
Did You Participate In Any Of Mercks (NYSE:MRK) Respectable 65% Return?Did You Participate In Any Of Merck's (NYSE:MRK) Respectable 65% Return?
ca.finance.yahoo.com - April 27 at 2:00 PM
This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.